- PharmaMar today announced that
Kahalalide F (KF), its marine-origin compound, has entered into Phase
II trials for the treatment of patients with severe psoriasis.
KF is currently undergoing Phase II clinical trials in various
tumours: melanoma, non-small lung cancer and hepatocarcinoma.
During the Phase I clinical trials on oncological patients treated
with KF, it was found that the compound had clinical potential to
treat severe psoriasis. These signs of activity, together with the
product's excellent safety profile, led to the initiation of the
clinical development of KF for psoriasis, thereby widening the range
of therapeutic applications for this compound beyond the field of
Regulatory authorities have approved the commencement of Phase II
studies on patients with psoriasis, which will be undertaken in
hospitals in both Spain and France.
This is not the first compound with anti-proliferative activity to
show both anti-tumoural and anti-psoriatic activity: methotrexate is
a clear example of such dual usage.
Approximately 100 million people worldwide suffer from psoriasis,
a chronic, non-contagious inflammation of the skin, characterised by
reddish plaques and patches with scales. It affects all ages, but it
is most prominent among adults (it is equally common among men and
women). The disease is difficult to treat and impairs patients'
quality of life.
Commenting on the announcement, Isabel Lozano, CEO of PharmaMar,
said: "PharmaMar continues to focus on advancing cancer care, however
where it makes sense to widen the range of therapeutic applications
for our compounds, we will explore the opportunity."
Notes to editors
Kahalalide F is one of a family of novel peptides isolated from
the Hawaiian mollusk, Elysia rufescens. It is currently in Phase II
trials for hepatocarcinoma.
PharmaMar is a biopharmaceutical company, advancing cancer care
through the discovery and development of innovative marine-derived
medicines. PharmaMar's clinical portfolio currently includes Yondelis
(TM) in phase II clinical trials (co-developed with Johnson & Johnson
Pharmaceutical Research & Development), designated Orphan Drug for
STS by the EMEA in 2001 and Orphan Drug for ovarian cancer in 2003;
Aplidin(R), in phase II, designated Orphan Drug for acute
lymphoblastic leukaemia in 2003; Kahalalide F in phase II and ES-285
in phase I clinical trials.
PharmaMar, based in Madrid, Spain, is a subsidiary of the Zeltia
Group (Spanish stock exchange: ZEL.MC; Bloomberg: ZEL SM; Reuters:
ZEL.MC). PharmaMar can be found on the Web at
ots Originaltext: Zeltia Group
Im Internet recherchierbar: http://www.newsaktuell.ch
Lola Casals, PharmaMar, Tel: +34-91-846-6000. James Strong & Deborah
Scott, Financial Dynamics, Tel: +44-207-831-3113